We have significant concerns about what it will do in terms of access. We do believe that it is going to cause concern within the pharmaceutical companies in terms of Canada as a marketplace, which in fact will restrict access, both when we look at clinical trials and the potential to come to Canada, as well as when we look at Canada as a marketplace for the new therapies we do see coming down the pipeline.
On December 3rd, 2020. See this statement in context.